<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1885">
  <stage>Registered</stage>
  <submitdate>17/03/2008</submitdate>
  <approvaldate>17/03/2008</approvaldate>
  <nctid>NCT00640458</nctid>
  <trial_identification>
    <studytitle>Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-Menopausal Women With Female Sexual Arousal Disorder</studytitle>
    <scientifictitle>A Double Blind, Placebo Controlled 2-Way Cross-Over Study to Assess the Clitoral Engorgement Response as Measured by Non-Contrast Magnetic Resonance Imaging (MRI) in Women With Female Sexual Arousal Disorder (FSAD) When Administered a Single Dose of Sildenafil (100mg) Followed by Audio/Visual Sexual Stimulation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A1481174</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Female Sexual Arousal Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sildenafil 100 mg
Treatment: drugs - Placebo

Placebo Comparator: Placebo - Study Period 1 or 2

Experimental: Experimental - Study Period 1 or 2


Treatment: drugs: Sildenafil 100 mg


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the % of subjects who respond within 30 minutes of dosing by achieving an increase in clitoral engorgement &gt;50% from baseline measured by MRI following audio/visual sexual stimulation in females with FSAD.</outcome>
      <timepoint>Up to 30 minutes post-dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the % of subjects who respond to sildenafil 100mg by achieving an increase in clitoral engorgement &gt;50% from baseline within 40, 50 and 60 minutes of dosing respectively.</outcome>
      <timepoint>Up to 60 minutes post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess safety and toleration of sildenafil 100mg by adverse event monitoring, laboratory safety testing and physical examination findings.</outcome>
      <timepoint>30 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess plasma levels of sildenafil and metabolite</outcome>
      <timepoint>Day of dosing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Pre-menopausal women aged 18-45 with a primary diagnosis of Female Sexual Arousal
             Disorder for at least 6 months prior to entering the study. The FSAD could have been
             associated with female orgasmic disorder (FOD) and/or superficial or introital
             dyspareunia.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with hypoactive sexual desire disorder.

          -  Subjects not using an acceptable mean of contraception for the duration of the study.

          -  Subjects who were prescribed and/or taking medication which were contraindicated or
             cautioned with concomitant intake of sildenafil.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Nedlands</hospital>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the effect of 100 mg sildenafil on clitoral
      engorgement in pre-menopausal women, as well as examining the safety and toleration of the
      drug.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00640458</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>